q1 loss per share $0.84.
q3 adjusted loss per share $0.54 excluding items.
q3 sales $351.9 million versus refinitiv ibes estimate of $298.1 million.
qtrly sales, excluding surcharge, were flat sequentially on 5% lower volume.
compname reports second quarter 2021 results; reaffirms full year 2021 guidance; announces $130 million share repurchase program.
q3 sg&a expenses $47.8 million versus refinitiv ibes estimate of $48.7 million.
qtrly medical end-use sales increased 7% sequentially.
for the balance of year, we currently expect to be in range of 28% to 30% tax rate.
sees at least $50 million of positive free cash flow in q4.
q3 sales decreased 40% on a 39% decrease in volume.
expect to spend about $110 million to $120 million on capital expenditures for fiscal year 2021.
q2 adjusted operating loss $29.7 million versus $32.3 million.
qtrly net sales $299.6 million versus refinitiv ibes estimate of $246.5 million.
qtrly net sales $64.9 million versus refinitiv ibes estimate of $65.7 million.
expect pension expense to be lower by about $3 million for fiscal 2022.
qtrly operating loss per share $40 million.
